Beraprost sodium |
Catalog No.GC38891 |
Le béraprost sodique, un analogue de la prostacycline, est une prodrogue stable et oralement active de la PGI2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 496807-11-5
Sample solution is provided at 25 µL, 10mM.
Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation[1].
Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity[1]. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell-cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions[1].
Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis[1]. Animal Model: 6-8-week-old C57Bl/6J Male Mice[1]
[1]. Li S, et al. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels.J Mol Med (Berl). 2019 Jun;97(6):777-791.
Average Rating: 5
(Based on Reviews and 11 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *